HIV-induced alteration in gut microbiota Driving factors, consequences, and effects of antiretroviral therapy
HIV-induced alteration in gut microbiota Driving factors, consequences, and effects of antiretroviral therapy
复制标题
DOI：
10.4161/gmic.32132
复制
发表时间：
2014-01-01
期刊：
影响因子：
12.2
通讯作者：
Palmer, Brent E.
中科院分区：
文献类型：
--
作者：
Lozupone, Catherine A.;Rhodes, Matthew E.;Palmer, Brent E.
与适应性免疫在调节肠道细菌和宿主之间相互作用中的重要作用一致，我们和其他四个研究小组最近报告了慢性HIV感染期间肠道微生物组成的显著变化。在这里，我们在这些其他研究的背景下评估我们的结果，并深入研究抗逆转录病毒疗法（ART）的影响。虽然接受ART的HIV阳性个体的肠道微生物群通常与HIV阴性个体的肠道微生物群不同，但ART恢复健康相关患病率的程度在细菌分类群中各不相同。最后，我们讨论了肠道微生物群改变的潜在驱动因素和健康后果。我们认为，了解HIV相关肠道微生物群变化的机制将阐明适应性免疫在塑造肠道微生物群组成中的作用，并为靶向微生物群的治疗奠定基础，以减缓HIV疾病进展并降低HIV感染者的肠道相关疾病风险。
Consistent with an important role for adaptive immunity in modulating interactions between intestinal bacteria and host, dramatic alteration in the composition of gut microbes during chronic HIV infection was recently reported by ourselves and independently by four other research groups. Here we evaluate our results in the context of these other studies and delve into the effects of antiretroviral therapy (ART). Although gut microbiota of HIV-positive individuals on ART usually does not resemble that of HIV-negative individuals, the degree to which ART restores health-associated prevalence varies across bacterial taxa. Finally, we discuss potential drivers and health consequences of gut microbiota alterations. We propose that understanding the mechanism of HIV-associated gut microbiota changes will elucidate the role of adaptive immunity in shaping gut microbiota composition, and lay the foundation for therapeutics targeting the microbiota to attenuate HIV disease progression and reduce the risk of gut-linked disease in people with HIV.